Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cohort 1 neo-adjuvant|DRUG: Cohort 2 neo-adjuvant|DRUG: Cohort 1 adjuvant|DRUG: Cohort 2 adjuvant
Sponsor: William Sikov MD
Collaborators: Yale University